Famoxin

famoxin Obesity medicate Famoxin gives Genset shot in the arm By Noah Barkin PARIS, Feb 6 (Reuters) - Investors scrambled to buy shares in French biotech firm Genset *GENX.LN* on Tuesday after the company announced pre-clinical tests showed its anti-obesity drug Famoxin was effective in treating laboratory mice. Genset said its star drug, for which it instantaneously plans to begin human clinical trials at the end of the year, had caused bombastic laboratory mice to lose weight without a change in their diet. The findings were published in the on-line edition of respected assiduity journal Proceedings of the National Academy of Sciences. If Famoxin passes human clinical trials, where many drugs fail, it would complete the groups dramatic transformation from genomics boutique to prospered drug developer. We will know if it working on macrocosm at the beginning of 2002, said Francois Hamon, analyst at CIC EIFB in Paris. I give the m a good chance of proving it works and developing...If you fatality to get a full essay, order it on our website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper